A B S T R A C T Factor IX, isolated from normal human plasma, was homogenous by polyacrylamide gel electrophoresis in urea and sodium dodecyl sulfate. On the latter, it migrated as a single polypeptide chain with or without reducing agents and had an apparent mol wt of 62,000. After iodination by chloramine-T, a single peak of 1251 was found on gels. Immunoelectrophoresis in agarose with rabbit antifactor IX sera gave a single arc against both isolated and partially purified factor IX preparations. The rabbit antibody was specific as it failed to inhibit the activities of prothrombin or factors VII or X in normal plasma. At an additional 20-fold dilution, factor IX activity was inhibited 50%.
A B S T R A C T Factor IX, isolated from normal human plasma, was homogenous by polyacrylamide gel electrophoresis in urea and sodium dodecyl sulfate. On the latter, it migrated as a single polypeptide chain with or without reducing agents and had an apparent mol wt of 62,000. After iodination by chloramine-T, a single peak of 1251 was found on gels. Immunoelectrophoresis in agarose with rabbit antifactor IX sera gave a single arc against both isolated and partially purified factor IX preparations. The rabbit antibody was specific as it failed to inhibit the activities of prothrombin or factors VII or X in normal plasma. At an additional 20-fold dilution, factor IX activity was inhibited 50%.
In a double-antibody radioimmunoassay, excess rabbit anti-human factor IX precipitated 90-95% of the 125I-human factor IX. Control without specific antibody gave 6-8%. Dilutions of a pool of normal human plasma paralleled dilutions of the isolated preparation and were used for the standard curve. Of 39 plasma samples from normal donors, the mean factor IX antigen level was 93% of that of a separate normal pool.
The radioimmunoassay detected the abnormal factor IX produced in patients on warfarin therapy. After Al(OH)3 adsorption of warfarin treated patient's plasma, factor IX antigen, but not activity, was present in the supemate. Samples from 28 patients on warfarin gave a mean factor IX clotting activity of 27% with a mean antigen of 69%. The antigen level from the warfarin group was significantly lower than the antigen level of the normal group (P < 0.001).
The factor IX antigen level was then assessed in 36 patients from 29 pedigrees with hemophilia B. The median antigen level was 17% of normal. The distribution of the antigen level was wide with two patients Received for publication 30 August 1976 and in revised form 7January 1977. around 100% of normal; only two had levels below the limits of resolution of the radioimmunoassay as currently performed (<2%). Within each of the five pedigrees in which more than one affected member was tested, activity and antigen levels were the same. The degree of neutralization of the antibody's inhibition of normal plasma by patient's plasma was highly correlated.
Additional evidence for the detection of abnormal protein was provided by immunodiffusion of plasmas concentrated by lyophilization. Reactions of complete identity occurred between normal, a warfarin treated and a hemophilia B subject's plasmas.
INTRODUCTION
Factor IX is a coagulant protein which is required for intrinsic clotting. Congenital defects occur as the X-linked syndrome, hemophilia B (Christmas disease), and account for one-fifth the cases of hemophilia. Acquired defects are most frequently associated with the dependence of factor IX upon vitamin K for synthesis as an active protein.
Factor IX levels are usually assessed kinetically as clotting activity. For assay, the degree of correction of the prolonged intrinsic clotting of hemophilia B plasma is measured. The normal range is wide, generally 50-150% as compared to a normal plasma pool, and precision is moderate at best. On the other hand, most antigen assays of factor IX have been indirect, based upon neutralization of an antibody's inhibition of factor IX clotting activity. Antibodies used have been either human circulating anticoagulants (1) or antisera prepared in rabbits against partially purified factor IX preparations (2) . However, tests with either of these preparations have lacked sensitivity, the lack of specificity has been an addiThe Journal of Clinical Investigation Volume 59 May 1977-900-910 900 tional problem with rabbit antisera. A significant advance has been reported by Orstavik et al. (3) in which a quantitative immunoelectrophoresis system was developed in a highly purified, though not monospecific, system. Heretofore, a direct assay of factor IX antigen has not been achieved with specific, precipitating antibody.
Demonstration of a circulating, nonfunctional factor IX protein in patients on vitamin K antagonists could be achieved by a comparison of clotting activity and antigen level. Coumarin anticoagulation produces an acquired defect in the activities of prothrombim and factors VII, IX, and X. In bovine prothrombin, deficient carboxylation of glutamyl residues near the amino terminus occurs (4) and a nonfunctional protein circulates. The amino terminal sequence of bovine factor IX is homologous with bovine prothrombin (5) , indicating an identical mechanism of action of the coumarins on these proteins. Although there has been no direct evidence for an abnormal, circulating human factor IX molecule, kinetic (6) and neutralization (7, 8) studies have suggested its presence.
Patients with hemophilia A have normal levels of factor VIII antigen (9) , and circulate an immunologically cross-reactive, nonfunctional protein. In von Willebrand's disease, inherited as an autosomal dominant trait, there are low levels of factor VIII antigen (9) such that there is either rapid clearance of an abnormal factor or decreased production. There is current controversy about the nature of the factor VIII antigen, von Willebrand's factor (10) , which raises questions as to the validity of the data for hemophilia A or its use as a model for other hemophilias.
In groups of patients with hemophilia B, the majority of cases have been associated with either undetectable (1, 11, 12) Factor IX was isolated from plasma and was used to produce a specific rabbit anti-factor IX antibody.
The antigen was then labeled for use in a radioimmunoassay with the rabbit antibody and goat antirabbit IgG sera. Antigen level was then compared to clotting activity in a series of normal subjects, a group of patients on warfarin therapy, and in patients from pedigrees with hemophilia B. A preliminary account of these results has been presented (14) .
METHODS
Subject samples. Normal plasma samples were taken from volunteer blood donors at the Puget Sound Blood Center. The age range of the control group was 18-60 yr and 54% were women. Samples from consecutive patients on warfarin therapy were taken from specimens submitted for prothrombin time measurements to the Hematology Laboratory, U. S. Public Health Service Hospital. Patients' charts were reviewed and samples were excluded where there was any evidence of concurrent liver disease. Patients from pedigrees with hemophilia B had samples drawn for routine or diagnostic testing under the Hemophilia Care Program of the Puget Sound Blood Center. They had received no blood products for 2 wk before drawing the sample. Samples were collected into 1/10th vol 0.12 M sodium citrate (pH 6.8), rendered platelet poor by final centrifugation at 45,000 g for 20 min, and were either assayed immediately or flash frozen in dry ice-ethanol and stored at -80°C before assay. (15) . Similar results were obtained with IgG (4 mg/ml) and goat anti-rabbit IgG (P 4, SA) from Antibodies Inc., Davis, Calif. (see legend, Fig. 3 ). Heparin agarose was prepared by the cyanogen bromide technique as previously described (16, 17) .
Materials
Purification of factor IX. This was accomplished by a modification of the previously described method for bovine factor IX (16, 17) . Normal blood was collected from volunteer donors into citrate-phosphate-dextrose and, after removal of erythrocytes, heparin (4 U/ml) was added to the plasma. For the initial purification step, BaCl2 ( 20 -ml washes of buffer containing 50 mM NaCl, 0.2 M NaCl, 0.3 M NaCl, and 0.5 M NaCl were applied. The breakthrough protein contained predominately prothrombin; the 0.2-M NaCl wash, prothrombin with some factor X; the second wash, factor X activity with some factor IX (up to 20% of that applied); and the 0.5-M wash, only factor IX activity. Where necessary, the effluent protein was concentrated to 1 mg/ml by ammonium sulfate (60%) after the chromatography. The entire purification procedure could be carried out in 33 h. The purification is summarized in Table I , where the final preparation contained 75 factor IX U/mg. Assays of 1:10 dilutions of the factor IX preparation (1 mg/ml) for prothrombin, factor VII, and factor X were equal to buffer control values. Gel electrophoresis of purified factor IX showed a single band in sodium dodecyl sulfate (Fig. IA) . It was also homogenous by disc-gel electrophoresis in urea (20) (not shown). Factor IX is more anodal than factor X in the latter gels but they migrate the same in sodium dodecyl sulfate.
Radioiodination. Factor IX was labeled with i25I by the chloramine-T method of Hunter (21) . To 100 ,ul factor IX (50-100 ,ug) in 25 IAl 0.5 M sodium phosphate buffer (pH 7.5) and 10 jAl Na 12sI (1,000 ,uCi), 10 IAI chloramine-T (3 j,g) was added and reacted for lOs. The reaction was stopped by the addition of 10 ,ul of a fresh solution of sodium metabisulfite (containing 8 j,g) and 10 lOI KI (2 mg) in the phosphate buffer. The sample was applied to a 0.5 x 20-cm column of G-50 Sephadex through which 200 mg bovine serum albumin had been run to prevent adsorption. The reaction tube was washed with an additional 100 ,ul of the phosphate buffer (containing 2 mg KI) which was then applied to the column and the column begun. Equilibration and elution of this column was performed with phosphate-buffered saline. In eight preparations, the initial elution peak contained from 5 to 30% of the total counts per minute. For the 10-s reaction as described above, factor IX clotting activity was unaltered by iodination. Gel electrophoresis of the radioiodinated factor IX gave a single sharp peak of radioactivity (Fig. 2 Radioimmunoassay. The double antibody system was adapted from the radioimmunoassay of Buchanan et al. (22) , employing final precipitation by goat anti-rabbit IgG. Rabbit anti-factor IX antibody was prepared by intradermal injections of Freund's adjuvants, emulsified with 0.5-1 mg aqueous antigen, and given 2-4 wk apart. Blood was collected at 7-14 days after the final boost and sera used for clotting assays was adsorbed with 1/10th vol AI(OH)3, which was removed by centrifugation (45,000 g, 20 min).
For the assay, anti-factor IX (10 ,ul, 1:400-1:5000 dilution in 1:5 normal rabbit sera or IgG) was added to 250-,ul tubes (Beckman Instruments, Inc., Fullerton, Calif.) containing dilutions of plasma samples (20 gl), and l25I-factor IX (20 ,ul 30 normal human subjects and the percent of normal determined from a plot of percent bound vs. log dilution (Fig. 3) . Dilution curves of isolated factor IX paralleled those of normal plasma. Using El cml%= 13.2 for human factor IX,' the level of factor IX protein in the normal plasma pool was 4.2,g/ml. The radioimmunoassay was sensitive to 2% of normal levels;2 for duplicate deter-' Desipio, R., and E. W. Davie. Unpublished results. 22% was the lowest level at which three or more dilution points could be compared with the dilution curve of normal plasma. minations, counts per minute agreed to within +5%. Data relating to experimental error is presented in results.
Clotting assays. Factor IX clotting activity was determined by a modification of the one-stage, kaolin-activated partial thromboplastin time (23) in which substrate plasma was from patients with severe congential hemophilia B who lacked neutralizing activity. For the assay, 0.1 ml deficient plasma, 0.1 ml 1:20-1:40 dilution of rabbit brain cephalin, and 0.1 ml kaolin (2% in 0.1 M NaCl) were preincubated with 0.1-ml sample (diluted in veronal buffer, 0.1 ionic strength, pH 7.5) for 2 min at 37°C, and then 0.1 ml 35 mM CaCl2 was added. The siliconized tubes were then tipped and timed until a visible clot was formed. Four dilutions of sample were assayed and compared to the log dilution vs. activity of a normal human plasma pool (30 donors).
The prothrombin time, partial thromboplastin time, and specific assays of prothrombin, factor VII, and factor X were performed as previously described (24) . The thrombotest was run according to Owren (25) with fibrometers (BioQuest, BBL & Falcon Products). For samples from the preparation before DEAE-Sephadex chromatography, heparin was adsorbed by ECTEOLA cellulose columns (24) before assay.
Neutralization of anti-factor IX inhibition was determined by using the factor IX assay in a method similar to that of Roberts et (27) .
RESULTS
The factor IX preparation was homogenous by polyacrylamide gel electrophoresis in urea or sodium dodecyl sulfate. With the latter, there was no change on reduction (Fig. 1A) indicating a single polypeptide chain, and the mol wt estimate was 62,000 (Fig. 1B) . When co-electrophoresed with bovine factor IX (17), the migration was identical (not shown). Factor IX was also homogenous by immunoelectrophoresis. As shown in Fig. 4 , rabbit antibody to partially purified or isolated factor IX gave single precipitin arcs when run against the purified factor IX antigen. Likewise, antibody to a partially purified factor IX gave a single arc against purified factor IX (Fig. 4) (Fig. 5 ).
Radioimmunoassay. With excess rabbit anti-factor IX (e.g. 1:30, 1:100), the second antibody precipitated 90-96% (e.g. Fig. 6 ) of counts in eight preparations of labeled antigen. When rabbit anti-factor IX was omitted from the assay, the pellet gave 6-8% of the initial antigen counts (without washing). For antigen level determinations, the absolute values were somewhat dependent upon experimental conditions (e.g. preincubation, concentration, and preparation of iodinated antigen or rabbit or goat anti-sera). Day to day variation of the standard curve was < ± 10% for a given set of conditions.
To assess experimental error, three separate dilutions were performed on plasma samples containing either near normal, half normal, or low antigen levels. The assay results were 118, 113, and 105% for a normal subject (whose levels had been 105 and 112 on previous assays); 52, 53, and 58% for a warfarin-FIGURE 5 Immunodiffusion in 0.5% agarose (27) . Center well contains rabbit antifactor IX serum (a) and plasma samples were concentrated by lyophilization and reconstitution with water to one-fifth starting volume. Plasma sample wells are numbered as follows: 1, 3, 5, and 7 are normal; 2 and 4 are hemophilia B (patients 12 and 1, respectively, from 28 patients on warfarin therapy in the order of their factor IX clotting activity. The mean prolongation of the prothrombin time was 23 s or 1.9 times normal; the thrombotest prolongation was strongly correlated (r = 0.76). Correlation of decreased factor IX activity with the prolongation of each of these extrinsic tests (for prothrombin time, r = -0.73; for thrombotest, r = -0.53) was varied but highly significant, such that the degree of anticoagulation is reflected by the factor IX clotting activity in this group. The mean clotting activity was 28%. The mean factor IX antigen level was 69% and dilution curves of each patient's plasma paralleled those of normal control plasma. The mean warfarin antigen level was significantly lower than that (93%) of the normal controls (t = 4.39, P < 0.001). In the warfarin group the correlation coefficient between factor IX clotting activity and antigen was r = 0.39 (P < 0.05). The logtransformed data comparing clotting activity to antigen levels are presented in Fig. 7 .
To demonstrate that the radioimmunoassay indeed oOo000 1/10,000 detects abnormal factor IX protein in warfarin pa-ANTIBODY DILUTION FIGURE 6 Antibody dilution curve of '25I-factor IX and specific rabbit anti-factor IX, demonstrating greater than 90% precipitation of labeled antigen at high antibody concentrations. treated patient (previously 53); and 14, 14, and 15% for a patient with hemophilia B (previously 15%), such that the reproducibility of-the assay was < + 10% of the given value throughout a wide antigen range.
Normal controls. Of the 39 normal control subjects, the mean factor IX clotting activity was 93% and the mean antigen level was also 93% (Table  II) . The correlation coefficient (r) for the activity vs. antigen was 0.39 (P < 0.02); with log transformed data, r was calculated as 0.52 (P < 0.001). Of note, when the data in Table II are rank ordered, Spearman's rho = 0.85. The distribution of log clotting activity vs. log antigen level is presented in Fig. 7 .
To assess the effect of increasing the number of data points on precision, samples from 10 subjects (see asterisks, Table II Table IV , in the order of their clotting activity level. The median factor IX clotting activity was 2% (range <1-25%) whereas the median antigen level was 17% (range <2-103%). Five pedigrees had more than one affected member tested and the activity and antigen levels were the same within each family (Table V) . Neutralization results correlated highly with the antigen level (Spearman's rho = 0.93, P < 0.001). For the 16 pedigrees with < 17% antigen, 12 were negative in the neutralization test with a lower concentration of rabbit anti-factor IX (1:200, final dilution) and 4 were weakly positive. When the neutraliza-906 A. R. Thompson The thrombotest, employing commercial ox-brain thromboplastin, was performed on patients from 28 pedigrees to determine if any represented the Bm variant described by Hougie (28) . B. is probably associated with high levels of a defective factor IX antigen, and is characterized by prolonged ox brain, but not human brain, extrinsic clotting. Partial correction of the thrombotest by 1: 1 mixture with normal plasma has been given as evidence for inhibition by the abnormal antigen. As shown in Table IV , seven of our patients had 250 s (longest normal was 53 s). Four of these seven were corrected to 42 s or less after 1:1 mixture with normal plasma. As expected, samples which corrected also had significant prolongation of the prothrombin times with human The radioimmunoassay used in the present study employs a highly purified antigen that was homog-enous by clotting activities, by gel electrophoresis in urea and sodium dodecyl sulfate, and by immunoelectrophoresis; it appeared unaltered by iodination. Properties of our factor IX preparation were quite similar to those of Rosenberg et al. (33) and Andersson et al. (34) who also employed heparin agarose chromatography. The preparation of Osterud and Flengsrud (35) utilized an immunoadsorption technique to remove factor X and, although homogenous electrophoretically, subsequent immunoelectrophoresis (3) detected two protein species. An additional problem with their preparation is that the amino terminus was reported as glycine whereas tyrosine has been found by Andersson et al. (34) and in another preparation similar to ours.' The apparent molecular weight by gel electrophoresis was somewhat higher in the three previous studies although our preparation had a migration that was clearly more anodal than prothrombin. When coelectrophoresed with bovine factor IX, the migrations were identical. Assuming the carbohydrate content of human factor IX to be similar to the bovine form, a somewhat lower molecular weight would be expected by sedimentation than the 62,000 estimated on gel electrophoresis (e.g. 55,400 [17] ).
The specificity of the antibody raised to factor IX was demonstrated by its failure to inhibit activities of other vitamin K-dependent clotting factors. Also, precipitation of over 90% of the iodinated antigen by antibody excess with only 6-8% binding in the controls without anti-factor IX (without washing the pellet), assure a high degree of specificity in the radioimmunoassay. Below 2% antigen, the parallel nature of dilution points could not be assessed adequately in the assay as it is presently performed. For greater sensitivity, a higher dilution of rabbit antifactor IX or a longer preincubation could be employed (both of which would decrease the precision [21] ). Alternatively, a rabbit antibody preparation with greater avidity might be obtained.
Although the factor IX activity and antigen levels were significantly correlated in normal subjects, the extent to which experimental error vs. biologic variation account for the variance from a linear relationship remains unclear. Additional dilutions and replicates improve precision (36) (Table III) . Furthermore, as illustrated in Fig. 7 , patients on warfarin with lower factor IX clotting activities, and thus higher degrees of anticoagulation, had increasing amounts of antigen as compared to clotting activity. In the extreme, patient 28 in Table III , there was more than eight times as much antigen as clotting activity and a reaction of complete identity with normal plasma was observed on immunodiffusion. Thus, the radioimmunoassay does detect the abnormal factor IX protein in these patients. The fact that the factor IX antigen level was significantly lower in the warfarin-treated group than in normals may reflect increased catabolism, as has been recently illustrated for human prothrombin by both crossed and quantitative immunoelectrophoresis (39) . Alternatively, decreased binding of abnormal factor IX to the rabbit anti-factor IX could explain the lower level. Concerning the latter, there is no direct evidence to exclude a quantitative difference, although the parallel nature of dilution curves in the radioimmunoassay rules against a qualitative or major quantitative difference in binding.
One would predict that patients with deficient vitamin K absorption would have a similar distribution of factor IX antigen due to decreased carboxylation. In severe liver disease, even lower levels of antigen would be found, due to the additive effect of decreased protein synthesis.
Hemophilia B. Previous studies have suggested that most cases of hemophilia B have factor IX antigen levels that are either undetectable or below normal. In similar-sized series, patients in about twothirds of the pedigrees have had no factor IX antigen as measured by neutralization of a human anti-factor IX (40, 11) . If the human factor IX antibodies are comparable to the circulating anticoagulants in hemophilia A (41), one would expect decreased sensitivity of human vs. rabbit antibody as the former is directed against fewer antigenic sites on the clotting factor molecule. Decreased sensitivity also accounts for the lack of neutralization in all but one factor IX pedigree studied by Elodi and Puska's (12) . A lack of sensitivity in their rabbit antibody, moreover, can be expected from its lower titer. In contrast, Meyer et al. (11) found 21 and 22 pedigrees positive for antigenic material with tlheir rabbit antibody. Their antibody preparation was nonspecific and detected at least fouir different antigens such that their positive results can be equally well explained by neutralization of other clotting factor activities in the final stage of their assay. The neutralization and immunoelectrophoretic data of Orstavik et al. (3) suggest that 6 of their 11 pedigree had levels below 7%. Although their system was a highly purified one, their antibody was not monospecific, the titer of their antifactor IX antibody was not given, and they ran their neutralization test in antibody excess (95% inhibition).
One-third of ouir pedigrees had a severe defect and one would predict that a series with predominately severe defects may have a higher percentage negative by neutralization tests, even with a specific antibody in high titer. The radioimmunoassay of factor IX represents a more sensitive and quantitative technique than those previously described, in addition to improved specificity. 6 of our pedigrees were entirely negative by the neutralization test and 10 more were weakly positive. However, only 2 of our 36 patients had antigen levels with dilution curves below the resolution of the radioimmunoassay as it is presently performed.
The correlation between neutralization and radioimmunoassay (0.93 in our series), the parallel nature of dilution curves, the presence of a wide distribution of antigen level itself, and the reaction of identity or immunodiffusion confirm that the radioimmunoassay detects abnormal factor IX antigen in patients with hemophilia B. Although a mutant protein could conceivably circulate without the same antigenic sites, rabbit antibodies are generally directed against several sites (specific sequences) in a protein of this size. Thus a mutation would at best lead to a relatively small quantitative difference in the binding of these antibodies. A mutation could alter the conformation of the proteins sufficiently to change all antigenic sites without allowing increased catabolism, but this mechanism, while theoretically possible, is unlikely to occur in plasma without altering the in vivo stability as well. The antigen levels found in our pedigrees with hemophilia B are most probably a close approximation of the circulating level of an abnormal factor IX protein.
